The Latest Cardiac and Vascular News
Opportunities Featuring Proprietary Surface Coated Technologies CARLSBAD, Calif., April 7, 2022 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, today announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking […]
NANJING, China, April 7, 2022 /PRNewswire/ — Triastek, Inc. (“Triastek”) recently announced that the United States Food and Drug Administration (FDA) has granted permission to begin clinical studies of its Investigational New Drug (IND) 505(b)(2) application for a 3D printed drug product – T20. It is Triastek’s second product receiving IND clearance from the […]
Albany, N.Y., April 07, 2022 (GLOBE NEWSWIRE) — When we get sick, our number one goal is to feel better as fast as possible. When people have heart attacks, their number one goal is to ensure it never happens again. Cardiac rehab is one of the best methods a person […]
KFAR-SABA, Israel and IRVINE, Calif., April 6, 2022 /PRNewswire/ — CathWorks, an original equipment manufacturer (OEM), and Quest International, a global service support provider to the OEMs, announced today they have signed a post-sales technical service support agreement that Quest International becomes the preferred technical service delivery partner for end-to-end service support of CathWorks’ fast-growing […]
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart that was presented on April 2nd at the American College of Cardiology (ACC) 71st Scientific Sessions […]
In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes Tyvaso DPI safety confirmed through 51 weeks of optional extension phase data with no study drug-related serious adverse events FDA action on […]
Combined Company to Spearhead Transformation of Cardiovascular Disease Drug Discovery and Development BOSTON, April 5, 2022 /PRNewswire/ — Valo Health, LLC (“Valo”), announced today the acquisition of TARA Biosystems, Inc. (“TARA”), a New York City-based cardiovascular disease biotechnology company, creating the first of its kind vertically integrated cardiovascular drug discovery and development platform. The combination of TARA’s proprietary […]
First clinical trial to evaluate the safety & efficacy of RT234 on exercise parameters assessed by Cardiopulmonary Exercise Testing (CPET) PALO ALTO, Calif., April 5, 2022 /PRNewswire/ — Respira Therapeutics, Inc. a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of […]
SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the “Company” or “Claritas“) today announced that the Australian Human Research Ethics Committee has approved the Company’s submission for the Phase 1 clinical study of R-107 to be conducted […]
Largest ever real-world analysis of Cardiac Implantable Electronic Device (CIED) infection treatment presented at the American College of Cardiology’s 71st Annual Scientific Session [1] demonstrates that approximately 4 in 5 patients are not treated according to HRS/EHRA Class I guidelines [2,3] for CIED infection In the absence of guideline-driven care, […]
